|Alexium International Group Limited -- Australia Stock|| |
AUD 0.4 0.01 2.44%
VP of RandD
Dr. Robert Brookins is Vice President Research Development of Alexium International Group Ltd. Dr. Brookins has broad experience in organic synthesis and materials chemistry. He received his PhD from the University of Florida under research advisor John R. Reynolds
VP Since 2015 Ph.D
61 8 9384 3160 http://www.alexiuminternational.com
Brookins? graduate work was in the synthesis and characterization of conjugated polyelectrolytes and polymers. Upon completion of his PhD, he worked at the Air Force Research Laboratory at Tyndall AFB where he developed decontamination methods for chemical and biological threats and novel synthetic routes for functional surfaces.
The company has return on total asset (ROA)
of (50.6) %
which means that it has lost $50.6 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (141.04) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 5.57 M in total debt with debt to equity ratio (D/E) of 84.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Alexium International Group Limited has Current Ratio of 2.77 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Alexium International Group Limited develops and sells chemical solutions for military and commercial applications in Australia and the United States. Alexium International Group Limited (AJX) is traded on Australian Securities Exchange in Australia. It is located in Perth, WA and employs 11 people.